Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept: ⭐️Seropositivity ⭐️no prior bMDARD use ⭐️low HAQ-DI ⭐️low BMI Abst#1228 #ACR21 @Rheumnow https://t.co/NvJoSWScZs